PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial
Cristina Arriens(Oklahoma Medical Research Foundation), Ronald F Van Vollenhoven(Amsterdam University Medical Centers), Ilias Kouris(Bristol-Myers Squibb (Switzerland)), Venkat S. Renukuntla(Baylor College of Medicine), Zahi Touma(University of Toronto), Marilyn C. Pike(Bethesda Hospital), Răzvan Ioniţescu(Newport Chemical Depot), Junyu Nie(Bristol-Myers Squibb (United States)), Masato Okada(St. Luke's International Hospital), Eric F Morand(Monash University), Victoria P Werth(Philadelphia VA Medical Center), JT Merrill(Oklahoma Medical Research Foundation), Yogita Kolekar(Bristol-Myers Squibb (United States)), Thomas Wegman(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
|Annals of the Rheumatic Diseases|2013|340
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure
|Kidney International|1999|305